MOTS-c (Mitochondrial Open Reading Frame of the 12S rRNA type-c) is a 16-amino acid peptide with a remarkable distinction: it is encoded not by nuclear DNA, but by the mitochondrial genome itself. This post provides a comprehensive research review of MOTS-c peptide, covering its unique biosynthetic origin, its well-characterised role in AMPK activation and glucose metabolism, emerging data on insulin sensitisation, aging model findings, and its relationship to other mitochondria-derived peptides including SS-31 and Humanin.
A Peptide Born in the Mitochondrial Genome
For decades, the mitochondrial genome was considered to encode only 13 proteins, all structural components of the oxidative phosphorylation machinery, alongside rRNA and tRNA sequences. The discovery of MOTS-c in 2015 by Lee et al. (Cell Metabolism) fundamentally revised this view. MOTS-c is encoded within the 12S ribosomal RNA gene of mitochondrial DNA (mtDNA), translated through a non-canonical mechanism, and subsequently translocated to the cytoplasm and, under certain stress conditions, to the nucleus.
This mitochondrial origin is not merely a genomic curiosity. It places MOTS-c at the intersection of two of the most heavily researched areas in longevity biology: mitochondrial function and inter-organelle signalling. Because mtDNA is maternally inherited and evolves at a different rate than nuclear DNA, MOTS-c represents a phylogenetically ancient signalling molecule, one that may have co-evolved alongside nuclear stress-response pathways over hundreds of millions of years. For researchers interested in the deep biology of aging, this evolutionary context makes MOTS-c peptide a particularly compelling subject of investigation. You can explore broader context on mitochondria-derived and other bioactive peptides in our What Are Research Peptides? Complete 2026 Guide.
AMPK Activation: The Core Metabolic Mechanism
The most consistently reported molecular action of MOTS-c in preclinical research is the activation of AMP-activated protein kinase (AMPK), a master regulator of cellular energy homeostasis. In the landmark 2015 Lee et al. study, MOTS-c treatment in murine models stimulated AMPK phosphorylation at Thr172, the canonical activation site, in skeletal muscle and other metabolically active tissues.
Mechanistically, MOTS-c appears to act upstream of AMPK by inhibiting the folate cycle and de novo purine biosynthesis. This inhibition leads to accumulation of the metabolic intermediate AICAR (5-aminoimidazole-4-carboxamide ribonucleotide), which itself is a well-characterised pharmacological activator of AMPK. In this way, MOTS-c functions as an endogenous trigger of the same pathway activated by exercise and caloric restriction, two of the most reproducible interventions for extending healthspan in model organisms.
Downstream consequences of MOTS-c-mediated AMPK activation include enhanced fatty acid oxidation, inhibition of mTORC1-dependent anabolic signalling, increased mitochondrial biogenesis via PGC-1α, and upregulation of antioxidant defences through Nrf2 pathway engagement. Researchers studying metabolic syndrome, type 2 diabetes models, or exercise mimetics will find the AMPK axis central to interpreting MOTS-c data.
Insulin Sensitivity and Glucose Metabolism Research
Parallel to its AMPK activity, MOTS-c peptide has demonstrated significant effects on insulin signalling and glucose disposal in multiple preclinical models. In diet-induced obese (DIO) mouse models, systemic administration of MOTS-c improved insulin tolerance test (ITT) outcomes, reduced fasting blood glucose, and attenuated hepatic lipid accumulation, all consistent with enhanced systemic insulin sensitivity.
At the cellular level, MOTS-c has been shown to promote glucose transporter GLUT4 translocation to the plasma membrane in skeletal muscle myotubes, a process that is AMPK-dependent and represents the dominant mechanism for insulin-stimulated glucose uptake in peripheral tissues. Importantly, this effect appeared to occur even under conditions of insulin resistance induced by palmitate exposure, suggesting that MOTS-c may exert some insulin-independent glucose-lowering activity.
A 2019 study by Kim et al. extended these findings to age-related insulin resistance, demonstrating that circulating MOTS-c levels decline with age in both mice and humans, and that this decline correlates with reduced insulin sensitivity. Exogenous MOTS-c administration in aged mice partially restored insulin responsiveness, positioning the peptide as a potential research tool for studying age-associated metabolic deterioration. Researchers investigating metabolic aspects of aging may also wish to review our Best Anti-Aging Research Peptides 2026 overview for comparative context.
Nuclear Translocation and the Stress Response Programme
One of the most scientifically striking properties of MOTS-c is its capacity to translocate from the cytoplasm to the nucleus in response to cellular stress, particularly oxidative stress and glucose restriction. This nuclear translocation, reported by Kim et al. in Nature Communications (2018), fundamentally repositions MOTS-c from a circulating metabolic hormone to an intracellular transcriptional regulator.
Once in the nucleus, MOTS-c has been shown to interact with the antioxidant response element (ARE) machinery, modulating the expression of stress-response genes including those regulated by ATF1 (activating transcription factor 1). This gene regulatory activity appears distinct from its cytoplasmic AMPK-activation role, suggesting that MOTS-c operates through at least two parallel mechanisms depending on the metabolic context.
This nuclear role connects MOTS-c to the concept of mitohormesis, the phenomenon whereby mild mitochondrial stress activates protective, longevity-associated gene expression programmes. The peptide may thus act as a direct molecular relay between mitochondrial dysfunction or stress and nuclear gene regulation, a communication axis that is increasingly recognised as fundamental to both aging biology and the adaptive response to exercise.
Aging Model Data and Longevity Research
MOTS-c research has produced encouraging data in multiple aging model systems. In C. elegans, a canonical longevity model, MOTS-c exposure extended mean lifespan under normal conditions and under oxidative stress challenge, with lifespan extension partially dependent on the worm homologue of AMPK (aak-2). In murine aging models, MOTS-c administration to aged mice improved grip strength, running capacity, and metabolic flexibility, phenotypes consistent with attenuation of the sarcopenic and metabolic decline that characterises mammalian aging.
Perhaps most intriguingly, a 2021 study demonstrated that MOTS-c levels are regulated in an exercise-dependent manner in humans, with plasma concentrations rising acutely following high-intensity exercise. This finding supports the hypothesis that MOTS-c functions as an exercise-inducible mitokine, a mitochondria-secreted peptide that mediates some of the systemic benefits of physical activity, including those on metabolic health, inflammation, and potentially longevity-related pathways.
For comparison with another mtDNA-relevant longevity research tool, researchers may find it useful to read our analysis of Epithalon Peptide: Telomerase & Longevity Research, which addresses a distinct but complementary angle on cellular aging at the level of telomere biology.
MOTS-c in Context: Comparison with SS-31 and Humanin
MOTS-c belongs to a broader, emerging class of peptides collectively termed mitochondria-derived peptides (MDPs). The two most studied other members of this class are Humanin and SS-31, and comparing their mechanisms offers useful research context.
Humanin is also encoded within the 12S rRNA gene of mtDNA, like MOTS-c, and shares a mitochondrial biosynthetic origin. However, Humanin acts primarily through extracellular receptors, including the formyl peptide receptor-like 1 (FPRL1/FPR2) and a tripartite receptor complex (CNTFR/WSX-1/gp130), to exert cytoprotective, anti-apoptotic, and neuroprotective effects. Its metabolic effects are less pronounced than those of MOTS-c. You can explore Stackpure’s Humanin Peptide Vial for in vitro research applications.
SS-31 (also known as Szeto-Schiller peptide 31 or Elamipretide) is a synthetic, nuclear-encoded tetrapeptide that targets cardiolipin on the inner mitochondrial membrane, directly protecting the electron transport chain from oxidative damage. Unlike MOTS-c, SS-31 does not originate from mtDNA; its mechanism is primarily structural and bioenergetic rather than transcriptional or metabolic signalling-based. Researchers studying mitochondrial membrane integrity and ROS-mediated pathology may find SS-31 complementary to MOTS-c investigations. Stackpure supplies SS-31 Peptide Vial for such research purposes.
Together, MOTS-c, Humanin, and SS-31 represent distinct research vectors into mitochondrial biology, differing in origin, receptor engagement, and downstream effects, making their parallel investigation valuable for comprehensive mitochondrial research programmes.
MOTS-c Research Formats Available at Stackpure
Stackpure supplies MOTS-c peptide in two research-grade formats, both manufactured to rigorous quality standards with certificate of analysis (CoA) documentation available via third-party HPLC and mass spectrometry verification. Researchers can review all testing documentation at our Lab Testing & COA page.
The MOTS-c Peptide Vial is the standard lyophilised format, suited for in vitro cell culture work, reconstitution-based dosing studies, and biochemical assays. Lyophilised peptides offer extended shelf stability and flexibility in reconstitution volume and vehicle selection.
The MOTS-c Nasal Spray provides a pre-formulated aqueous delivery format, which may be useful for researchers designing in vivo rodent delivery protocols where consistent mucosal absorption kinetics are relevant to the study design.
Researchers building broader mitochondrial or metabolic longevity panels can also explore the full range of anti-aging and longevity peptides in our Full Research Catalog, or use the AI Stack Builder to identify scientifically coherent peptide combinations for specific research objectives.
Frequently Asked Questions
What makes MOTS-c peptide different from other research peptides?
MOTS-c is unique in being encoded within the mitochondrial genome, specifically within the 12S ribosomal RNA gene, rather than by nuclear DNA. This makes it one of only a small number of known peptides of mitochondrial origin, categorised as a mitochondria-derived peptide (MDP). Its dual capacity to activate AMPK in the cytoplasm and translocate to the nucleus as a transcriptional modulator further distinguishes it mechanistically from nuclear-encoded signalling peptides.
How does MOTS-c activate AMPK?
Research indicates that MOTS